-
Sector Analysis
NewNew Drug Approvals and Their Contract Manufacture – 2024 Edition
This report is the 14th edition of our long-running analysis of the CMO industry, using the FDA's NDA approvals as the primary indicator of performance. New Drug Approvals and Their Contract Manufacture (formerly called "CMO Scorecard") is critical for benchmarking the performance of the contract manufacturing organization (CMO) industry and the relative performance of major CMOs. This year's edition includes a discussion of how inflation and increasing global conflict has impacted pharma manufacturers.
-
Product Insights
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Nuclear factor (erythroid-derived 2)-like 2 or Nrf2 is a transcription factor encoded by the NFE2L2 gene. It binds to antioxidant response elements in the promoter regions of target genes. It is important for the coordinated up-regulation of genes in response to oxidative stress. It is involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region. The Nuclear Factor Erythroid 2 Related Factor 2 - Drugs...
-
Product Insights
COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2021
COVID-19 enzyme immuno assay/enzyme linked immunosorbent assay (EIA/ELISA) is the most widely used assays having high sensitivity and specificity. They are used to detect the recombinant protein and peptide antigens in the samples. The COVID-19 EIA/ELISA pipeline product report provides comprehensive information about the pipeline products with comparative analysis at various stages of development and information about the clinical trials which are in progress. The report also provides key information and clinical trial data regarding ongoing clinical trials such as...
-
Product Insights
COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) – Medical Devices Pipeline Assessment, 2020
COVID 19 EIA/ELISA are the most widely used assays having high sensitivity and specificity. They are used to detect the recombinant protein and peptide antigens in the samples. ELISA’s are specifically designed to screen large number of samples at a time. GlobalData's Medical Devices sector report, “COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) -Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) pipeline products with comparative analysis of...
-
Sector Analysis
Contract Manufacturing Service Agreements – Rising Manufacturing Opportunities Driven by Pharmaceutical Pipeline Expansion
This report is a brand new publication covering contract service agreements, across a range of different services and manufacturing scales. The number of contract service agreements secured serves as a primary indicator of a CMO's performance. Contract Manufacturing Service Agreements is critical for establishing an understanding of the overall CMO industry, the range of services provided and the features of some of the largest CMOs participating in the industry.
-
Thematic Analysis
3D Printing in Oil & Gas – Thematic Research
3D printing, or “additive manufacturing”, is the process of joining materials to make objects from three-dimensional model data, usually layer upon layer. In 2013, the 3D printing industry was worth $3bn, and grew to $7bn in 2017. By 2025, the 3D printing market will account for over $20bn in spend. The 3D printing market blends software technology with materials science and the growth in interest in 3D printing technology is fueling a significant amount of R&D investment in the core...